Cargando…
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758655/ https://www.ncbi.nlm.nih.gov/pubmed/34625861 http://dx.doi.org/10.1007/s10549-021-06374-6 |
| _version_ | 1784632956738863104 |
|---|---|
| author | De Laurentiis, Michelino Borstnar, Simona Campone, Mario Warner, Ellen Bofill, Javier Salvador Jacot, William Dent, Susan Martin, Miguel Ring, Alistair Cottu, Paul Lu, Janice Ciruelos, Eva Azim, Hamdy A. Chatterjee, Sanjoy Zhou, Katie Wu, Jiwen Menon-Singh, Lakshmi Zamagni, Claudio |
| author_facet | De Laurentiis, Michelino Borstnar, Simona Campone, Mario Warner, Ellen Bofill, Javier Salvador Jacot, William Dent, Susan Martin, Miguel Ring, Alistair Cottu, Paul Lu, Janice Ciruelos, Eva Azim, Hamdy A. Chatterjee, Sanjoy Zhou, Katie Wu, Jiwen Menon-Singh, Lakshmi Zamagni, Claudio |
| author_sort | De Laurentiis, Michelino |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8758655 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87586552022-01-26 Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population De Laurentiis, Michelino Borstnar, Simona Campone, Mario Warner, Ellen Bofill, Javier Salvador Jacot, William Dent, Susan Martin, Miguel Ring, Alistair Cottu, Paul Lu, Janice Ciruelos, Eva Azim, Hamdy A. Chatterjee, Sanjoy Zhou, Katie Wu, Jiwen Menon-Singh, Lakshmi Zamagni, Claudio Breast Cancer Res Treat Correction Springer US 2021-10-08 2022 /pmc/articles/PMC8758655/ /pubmed/34625861 http://dx.doi.org/10.1007/s10549-021-06374-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction De Laurentiis, Michelino Borstnar, Simona Campone, Mario Warner, Ellen Bofill, Javier Salvador Jacot, William Dent, Susan Martin, Miguel Ring, Alistair Cottu, Paul Lu, Janice Ciruelos, Eva Azim, Hamdy A. Chatterjee, Sanjoy Zhou, Katie Wu, Jiwen Menon-Singh, Lakshmi Zamagni, Claudio Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| title | Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| title_full | Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| title_fullStr | Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| title_full_unstemmed | Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| title_short | Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| title_sort | correction to: full population results from the core phase of compleement-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758655/ https://www.ncbi.nlm.nih.gov/pubmed/34625861 http://dx.doi.org/10.1007/s10549-021-06374-6 |
| work_keys_str_mv | AT delaurentiismichelino correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT borstnarsimona correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT camponemario correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT warnerellen correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT bofilljaviersalvador correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT jacotwilliam correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT dentsusan correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT martinmiguel correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT ringalistair correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT cottupaul correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT lujanice correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT cirueloseva correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT azimhamdya correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT chatterjeesanjoy correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT zhoukatie correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT wujiwen correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT menonsinghlakshmi correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation AT zamagniclaudio correctiontofullpopulationresultsfromthecorephaseofcompleement1aphase3bstudyofribociclibplusletrozoleasfirstlinetherapyforadvancedbreastcancerinanexpandedpopulation |